Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Circadian Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension

Orzalesi, N.; Rossetti, Luca; Bottoli, A.; Fogagnolo, Paolo

doi:10.1016/j.ophtha.2005.10.045

Cited by 113 publications

(85 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21,22 Although travoprost monotherapy has shown a meaningful IOP efficacy in the short term, [11][12][13][14][15][16] there is limited information on the long-term efficacy (Z12 mo). 23 However, previous clinical trials with latanoprost monotherapy, another prostaglandin analogue, have established a long-lasting daytime hypotensive effect with little evidence of tachyphylaxis, for up to 4 years.…”

Section: Discussionmentioning

confidence: 99%

“…4,17 Importantly, 24-hour studies have confirmed that 24-hour IOP monitoring can significantly modify individualized glaucoma care in many glaucoma patients. 18,19 A few 24-hour studies have investigated travoprost efficacy over a period of up to 4 months, [11][12][13]20 but to date no evidence is available for the long-term 24-hour efficacy of travoprost monotherapy in glaucoma.Therefore, the primary aim of this study was the evaluation of the long-term 24-hour IOP efficacy obtained by travoprost monotherapy, used as a first-line therapy during a 5-year follow-up period. A secondary aim was to investigate the survival rate without progression of a POAG cohort treated with travoprost monotherapy.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

“…9 Travoprost is increasingly becoming a popular first-line monotherapy option for POAG patients 10 as there is cumulative evidence suggesting good quality of shortterm 24-hour IOP control with low fluctuation, especially with evening administration. [11][12][13] However, although several controlled studies have demonstrated the daytime short-term efficacy of travoprost monotherapy, [14][15][16] little is currently known about its long-term efficacy.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Riva

Katsanos

Floriani

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

Purpose: The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients.Patients and Methods: A total of 36 previously untreated primary open-angle glaucoma patients were enrolled in this 5-year study.Patients underwent an untreated 24-hour IOP evaluation. Subsequently all patients were assigned to topical therapy with travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered once in the evening (8:00 PM) in both eyes. All patients were then scheduled for a 24-hour IOP assessment approximately 12 months after the baseline visit. This schedule of follow-up was maintained for the whole duration of the trial. The predetermined range of target IOP reduction selected in this cohort of patients ranged between 20% and 30%.Results: A total of 34 patients completed all phases of the investigation. The mean survival time was 57.3 ± 2.0 months and the cumulative survival rate was 0.82 ± 0.6 at 60 months. Travoprost reduced the mean 24-hour IOP from 23.4 ± 1.7 mm Hg at baseline to 16.8 ± 2.4 mm Hg (28.4%), 16.8 ± 2.5 mm Hg (28.1%), 16.8 ± 2.4 mm Hg (28.5%), 16.7 ± 2.5 mm Hg (28.6%), and 16.9 ± 2.4 mm Hg (27.8%), respectively at the end of the first, second, third, fourth, and fifth year follow-up. No drug-related serious adverse events were registered during the study.Conclusions: The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma.Key Words: open-angle glaucoma, prostaglandin analogue, circadian intraocular pressure, travoprost (J Glaucoma 2014;23:535-540) R eduction of intraocular pressure (IOP) is the only currently available, evidence-based management strategy in patients affected with primary open-angle glaucoma (POAG). Most POAG patients will require lifelong medical therapy to avoid visual loss. The decision to select medical therapy options relies primarily on the efficacy of the available medications in various therapeutic trials. Sadly, most published studies only evaluate the short-term, daytime efficacy of medical therapy.Prostaglandin analogues have become a popular firstline therapy option for lowering IOP in POAG owing to their superior 24-hour efficacy, 1-6 convenient once-a-day administration, 5 and favorable systemic safety profile. 7 Travoprost is a synthetic prostaglandin F2a analogue that exerts its IOP-lowering effect through the prostaglandin FP receptors situated at the ciliary muscle 8 and the trabecular meshwork. 9 Travoprost is increasingly becoming a popular first-line monotherapy option for POAG patients 10 as there is cumulative evidence suggesting good quality of shortterm 24-hour IOP control with low fluctuation, especially with evening administration. 11-13 However, although several controlled studies have demonstrated the daytime short-term efficacy of travoprost monotherapy, [14][15][16] little is currently known about its long-term efficacy.As POA...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Riva

Katsanos

Floriani

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Hastaların demografik özellikleri ve tedaviye başlanmadan ölçülmüş olan ilaçsız göz içi basıncı ortalamaları Tablo 1'de gösterilmiştir. Grupların yaş ortalamaları, cinsiyet dağılımları ve ilaçsız göziçi basınçları arasında istatistiksel olarak anlamlı bir fark saptanmamıştır (p>0,05) (Tablo 1 17,18 PAAG ve OH'li hastalarda 12 ay boyunca latanoprost ve travoprostun etkilerinin karşılaştırıldığı bir diğer çalışmada, tedaviye başladıktan iki hafta sonra yapılan kontrolde GİB değerleri benzer bulunmuştur. 4 Başka bir çalışmada bir ay boyunca latanoprost ve bimatoprost kullanan hastalar arasında GİB değerleri arasında fark saptanmamıştır.…”

Section: Bulgularunclassified

Primer Açık Açılı Glokomlu ve Oküler Hipertansiyonlu Hastalarda Latanoprost, Bimatoprost ve Travoprostun Etkinliğinin Karşılaştırılması

Çolak¹,

Yildirim²,

Uslu³

et al. 2014

tjo

View full text Add to dashboard Cite

Amaç:Primer açık açılı glokomlu (PAAG) ve oküler hipertansiyonlu (OH) hastalarda latanoprost, bimatoprost ve travoprostun göz içi basıncı (GİB) ve görme alanı üzerine etkilerini prospektif olarak karşılaştırmak. Gereç ve Yöntem: Kliniğimizde tanı konularak tedaviye başlanan PAAG ve OH'li 73 hastanın 124 gözü incelendi. Hastaların tümü 22-34 mmHg arasında GİB değerlerine sahip olup, erken dönemde tanı konulmuş ve daha önce herhangi bir tedavi uygulanmamış hastalardı. Rastgele olarak üç gruba ayrılmış olan PAAG ve OH'li hastalardan ilk grupta yer alan 42 göze latanoprost (%0,005), ikinci gruptaki 40 göze bimatoprost (%0,03) ve üçüncü gruptaki 42 göze travoprost (%0,004) uygulandı. Görme alanı değerlendirilmesinde Humprey Statpac istatistik programının ortalama sapma (mean deviation=MD) ve patern standart sapma (patern standart deviation=PSD) verileri kullanıldı. GİB, MD ve PSD değerleri başlangıçta ve tedavi sonrası birinci yılda ölçülerek karşılaştırıldı. Bulgular: Tedavi öncesi ve birinci yıl GİB değişim ortalamaları latanoprost, bimatoprost ve travoprost gruplarında sırasıyla; 6,99, 6,79 ve 5,87 mmHg olarak saptandı. Üç grupta da istatistiksel olarak anlamlı düşüş görüldü (p<0,001). GİB 'yi düşürme miktarı bakımından gruplar arasında istatistiksel olarak anlamlı bir fark bulunmadı. Latanoprost, bimatoprost ve travoprost gruplarının başlangıç ve birinci yıl MD ve PSD değerlerinde gruplar arasında istatistiksel olarak anlamlı fark yoktu (p>0,05). Bir yıl süreli tedavi sonrasında, MD ve PSD değerlerindeki değişim yönünden tedavi grupları arasında istatistiksel olarak anlamlı bulunmadı (p>0,05). Sonuç: PAAG ve OH'li hastalarda latanoprost, bimatoprost ve travoprost GİB'yi etkili olarak düşürmektedir. Bir yıl süreli tedavi sonrasında GİB ve görme alanı üzerine etkileri bakımından üç ilaç arasında anlamlı fark saptanmamıştır. (Turk J Ophthalmol 2014; 44: 170-4) Anah tar Ke li me ler: Latanoprost, bimatoprost, travoprost, göz içi basıncı, görme alanı Objectives: The aim of this prospective study was to compare the efficacy of latanoprost, bimatoprost, and travoprost in lowering intraocular pressure (IOP) and in preventing or delaying visual field loss in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH). Materials and Methods:The study included 124 eyes of 73 patients who were diagnosed in our clinic as having POAG or OH. All of the patients had IOP values of 22-34 mmHg, an early diagnosis of POAG or OH, without any previous treatment. The patients were randomly divided into 3 Groups: Group 1; 42 eyes treated with latanoprost (0.005%), Group 2; 40 eyes treated with bimatoprost (0.03%), and Group 3; 42 eyes treated with travoprost (0.004%). The visual field has been evaluated via the Humprey visual field evaluation of statistical program Statpac mean deviation (MD) and pattern standard deviation (PSD). The IOP, MD, and PSD values have been measured initially and at the end of the first year of treatment. Results: In comparison to the baseline, the mean changes of IOP values after one year of...

show abstract

Latent Asymmetric Intraocular Pressure as a Predictor of Visual Field Defects

et al. 2008

View full text Add to dashboard Cite

To investigate the association of latent asymmetric intraocular pressure (IOP) (IOP asymmetry between fellow eyes when patients were in the supine position but not when sitting) with visual field (VF) defects in patients with open-angle glaucoma. Methods: Fifty-three patients with open-angle glaucoma, who were receiving the same topical medication in both eyes, were enrolled and were housed in a sleep laboratory for 24 hours. Intraocular pressures were measured when the patients with open-angle glaucoma were in the supine position or were sitting. A group of patients with latent asymmetric IOP was identified. Intraocular pressure asymmetry, monocular diurnal IOP fluctuation, and VF indexes were compared between the groups with and without latent asymmetric IOP.

show abstract

Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Circadian Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension

Cited by 113 publications

References 43 publications

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Primer Açık Açılı Glokomlu ve Oküler Hipertansiyonlu Hastalarda Latanoprost, Bimatoprost ve Travoprostun Etkinliğinin Karşılaştırılması

Latent Asymmetric Intraocular Pressure as a Predictor of Visual Field Defects

Contact Info

Product

Resources

About